Blinatumomab – November 2024

• Brand names:
  • Blincyto®
• Pharmaceutical Company:
  • AMGEN AUSTRALIA PTY LIMITED
• Condition/Indication: Measurable residual disease (MRD)-negative B-cell precursor acute lymphoblastic leukaemia (B-ALL)
• Meeting Date: November 2024
• Public Summary Document (PSD) July 2024 November 2024 PBAC Meetings - (PDF 1.2KB)
• Public Summary Document (PSD) July 2024 November 2024 PBAC Meetings - (Word 636KB)

Related Public Summary Documents

• Blinatumomab – July 2024